Migraine is a common neurologic disorder that significantly impacts a patient’s quality of life and ability to work and is costly to treat. Although numerous agents have been available for preventing migraine, none was specifically designed to target the underlying pathologic process. The new class of agents is targeting one of these underlying pathologic processes.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Managed Care Medicine|
|State||Published - 2019|
ASJC Scopus subject areas
- Health Policy